BLA 761041 · Genentech INC
Tecentriq
Atezolizumab · Injection
Breakthrough therapyPriority reviewLast checked: Nov 20, 2026Latest source record: Oct 18, 2016 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2016
Oct 18, 2016
Approved uses
1
Original approval plus efficacy supplements
Registered trials
858
134 Phase 3, 179 recruiting
FAERS reports
39,719
37,952 serious, 10,079 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Oct 18, 2016 Original approval · Type 9 - New indication submitted as distinct BLA, consolidated · priority review Breakthrough therapyLabelLetterMedication Guide
1 products under this application
- TECENTRIQ · ATEZOLIZUMAB 1200MG/20ML · INJECTABLE, INJECTION · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Atezolizumab" as an intervention, any sponsor and status, largest first.
- Efficacy and Biomarker Development for Lung Cancer Treated With Immune Checkpoint InhibitorsPivotal-lookingRecruiting
Hunan Province Tumor HospitalAcademic, hospital or other
NCT05055908 · 12,000 participants (planned) · Start Oct 1, 2021 · Primary completion Jul 1, 2025
Drug: Pemetrexed plus Pembrolizumab; Pembrolizumab and 1 more · For: Lung Cancer
Sites: Changsha, China
- Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored StudyPivotal-lookingEnrolling by invitation
ExelixisIndustry
NCT07620574 · 5,000 participants (planned) · Start Jul 30, 2026 · Primary completion May 31, 2030
Drug: Cabozantinib; Zanzalintinib and 5 more · For: Cancer; Renal Cell Carcinoma (RCC); Pancreatic Neuroendocrine Tumors (pNET) and 6 more
Sites: Bay Shore, New York; Kettering, Ohio; Memphis, Tennessee · 4 sites in all
American Society of Clinical OncologyAcademic, hospital or other
NCT02693535 · 4,200 participants (planned) · Start Mar 14, 2016 · Primary completion Dec 31, 2027
Drug: Sunitinib (CLOSED TO ENROLLMENT); Trastuzumab and Pertuzumab (CLOSED TO ENROLLMENT) and 10 more · For: Lymphoma, Non-Hodgkin; Multiple Myeloma; Advanced Solid Tumors
Sites: Birmingham, Alabama; Phoenix, Arizona; Auburn, California · 181 sites in all
Oslo University HospitalAcademic, hospital or other
NCT04817956 · 3,000 participants (planned) · Start Apr 1, 2021 · Primary completion Mar 30, 2040
Drug: Atezolizumab · For: Cancer Metastatic
Sites: Ålesund, Norway; Bergen, Norway; Bodø, Norway · 17 sites in all
- A Study Comparing Atezolizumab (Anti PD-L1 Antibody) In Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone In Patients With Operable Triple-Negative Breast CancerPivotal-lookingTerminated
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT03498716 · 2,199 participants · Start Aug 2, 2018 · Primary completion Aug 14, 2023
Drug: Atezolizumab; Paclitaxel and 2 more · For: Triple Negative Breast Cancer
Sites: Concord, California; Los Angeles, California; St. Helena, California · 364 sites in all
The Netherlands Cancer InstituteAcademic, hospital or other
NCT02925234 · 1,550 participants (planned) · Start Aug 2016 · Primary completion Sep 2027
Drug: Panitumumab; Olaparib and 35 more · For: Cancer; Tumors; Neoplasm and 1 more
Sites: Alkmaar, Netherlands; Almelo, Netherlands; Amersfoort, Netherlands · 36 sites in all
- Clinical Trial of Neoadjuvant Chemotherapy With Atezolizumab or Placebo in Patients With Triple-Negative Breast Cancer Followed After Surgery by Atezolizumab or PlaceboPivotal-lookingActive, not recruiting
NSABP Foundation IncResearch network
NCT03281954 · 1,550 participants · Start Dec 19, 2017 · Primary completion Dec 31, 2024
Drug: Placebo; Atezolizumab · For: Triple Negative Breast Cancer
Sites: Mobile, Alabama; Anchorage, Alaska; Jonesboro, Arkansas · 217 sites in all
- The Effect of Serum Ferritin in irAERecruiting
Tianjin Medical University Cancer Institute and HospitalAcademic, hospital or other
NCT06702566 · 1,500 participants (planned) · Start Jul 4, 2024 · Primary completion Jul 16, 2026
Drug: PD-1 and PD-L1 inhibitor; Targeted drugs and 1 more · For: Immune-related Adverse Event; Malignant Solid Tumors; Acute Leukemia and 1 more
Sites: Tianjin, China
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- death4,361
- off label use3,721
- disease progression2,260
- pyrexia1,803
- diarrhoea1,750
- fatigue1,560
- anaemia1,387
- pneumonia1,160
- decreased appetite1,143
- hypothyroidism1,132
- nausea1,095
- dyspnoea1,061
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2011 | 1 |
| 2012 | 1 |
| 2014 | 3 |
| 2015 | 25 |
| 2016 | 603 |
| 2017 | 1,159 |
| 2018 | 1,889 |
| 2019 | 2,604 |
| 2020 | 3,354 |
| 2021 | 5,267 |
| 2022 | 5,804 |
| 2023 | 5,878 |
| 2024 | 5,155 |
| 2025 | 4,659 |
| 2026 | 3,317 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Tecentriq (Atezolizumab)
2024 spending
$23.0M
Beneficiaries
410
2,145 claims
Per beneficiary
$56,037
$522.51 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $12,942,335 |
| 2021 | $14,535,133 |
| 2022 | $24,590,543 |
| 2023 | $28,732,491 |
| 2024 | $22,975,155 |
Part B: Tecentriq (Atezolizumab) · HCPCS J9022
2024 spending
$678M
Beneficiaries
10,191
63,083 claims
Per beneficiary
$66,497
2024 ASP limit $85.24 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $624,194,084 |
| 2021 | $656,074,899 |
| 2022 | $777,758,575 |
| 2023 | $755,223,832 |
| 2024 | $677,665,952 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma.
Finn RS, Qin S, Ikeda M, et al. · N Engl J Med 2020 · Clinical Trial, Phase III, Multicenter Study
- First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer.
Horn L, Mansfield AS, Szczwsna A, et al. · N Engl J Med 2018 · Clinical Trial, Phase III, Multicenter Study
- Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma.
Cheng AL, Qin S, Ikeda M, et al. · J Hepatol 2022 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis.
Wang DY, Salem JE, Cohen JV, et al. · JAMA Oncol 2018 · Meta-Analysis, Systematic Review
- ctDNA-Guided Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer.
Powles T, Kann AG, Castellano D, et al. · N Engl J Med 2025 · Randomized Controlled Trial, Clinical Trial, Phase III
- Efficacy and safety of first-line maintenance therapy with lurbinectedin plus atezolizumab in extensive-stage small-cell lung cancer (IMforte): a randomised, multicentre, open-label, phase 3 trial.
Paz-Ares L, Borghaei H, Liu SV, et al. · Lancet 2025 · Randomized Controlled Trial, Clinical Trial, Phase III
Sponsor: Roche (Genentech)
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.